Melanotan II: Tanning, Libido, and Serious Safety Cautions

Melanotan II Overview & Molecular Profile

MECHANISM OF ACTION

Melanotan II is a cyclic lactam analog of alpha-melanocyte stimulating hormone (α-MSH) developed at the University of Arizona by Hruby et al. in the late 1980s. It is a non-selective pan-melanocortin agonist activating MC1R (pigmentation), MC3R/MC4R (sexual function and appetite), and MC5R—producing multiple simultaneous biological effects. Its sexual arousal side effect discovered during tanning trials led to the development of PT-141 (Bremelanotide), the only FDA-approved derivative. Melanotan II itself has no approved clinical indication.

Mechanism of Action: Receptor Agonism & Metabolic Pathways

MOLECULAR STRUCTURE

Melanotan II is a non-selective melanocortin receptor agonist, affecting MC1R (pigmentation), MC3R, MC4R (sexual function, appetite), and MC5R. By activating MC1R on melanocytes, it stimulates melanin production. Its effects on MC3R and MC4R influence sexual behavior and appetite regulation.

Melanogenesis

Research demonstrates Melanotan II's potent melanogenic effects through direct activation of melanocortin-1 receptors (MC1R) on melanocytes, triggering increased tyrosinase activity and eumelanin production that results in progressive skin darkening. Clinical studies have documented significant increases in melanin index scores within 2-4 weeks of administration, with enhanced tanning response to UV exposure and photoprotection research applications. The peptide induces melanin synthesis through cyclic AMP pathway activation, phosphorylation of CREB transcription factors, and upregulation of melanogenesis-related genes including MITF and TYR. Research has shown that Melanotan II can produce visible skin pigmentation changes even without sun exposure, though UV radiation synergistically enhances the tanning effect and provides more natural appearance outcomes. These melanogenesis promotion properties have significant implications for skin pigmentation research, photoprotection mechanism studies, and understanding the molecular basis of melanin production for potential vitiligo treatment applications and sun damage prevention investigations.

Appetite Modulation

Research indicates Melanotan II produces significant appetite-suppressing effects through activation of melanocortin-4 receptors (MC4R) located in the paraventricular nucleus and other hypothalamic regions controlling food intake and energy balance. Animal studies have demonstrated reduced food consumption, decreased body weight gain, and altered feeding behaviors following chronic Melanotan II administration, with effects mediated through the central melanocortin-leptin signaling axis. The peptide's anorectic properties appear to involve modulation of neuropeptide Y (NPY) and agouti-related peptide (AgRP) neurons that normally stimulate appetite, creating a shift toward reduced hunger signals. Clinical observations have noted decreased appetite and potential weight management effects in human subjects receiving Melanotan II for other research purposes. These appetite regulation effects have generated interest in melanocortin pathway research for obesity treatment development, eating disorder mechanisms, and understanding the complex neuroendocrine control of energy homeostasis and metabolic health improvement.

Research Protocol Doses Reported in Published Literature

Research Disclaimer: Doses reported below are from published preclinical research protocols. Melanotan II is not approved for human use by the FDA or any regulatory agency. This information is provided for research reference only and does not constitute a dosing recommendation. All doses above are reported from published research protocols using laboratory subjects. Refer to the cited studies in the Research Studies section above for original source data.

Safety & Contraindications

Melanotan II is a research compound and is not FDA-approved for general use. It should be avoided by anyone with atypical moles / dysplastic nevi, history of melanoma or skin cancer, cardiovascular disease, and pregnancy. Most reported effects are mild and dose-dependent, so start at the low end of the dosing range and titrate up slowly rather than chasing a maximal dose. Injection-site redness, itching, or a temporary lump are the most common local reactions; rotate sites and use clean technique to keep them minimal.

What to Monitor

Track body weight, systolic blood pressure, and diastolic blood pressure while you're running Melanotan II so you can catch any drift early and adjust before it becomes a problem. Add these to your REGEN biomarker dashboard and re-check on your normal cadence.

Key Findings at a Glance

• Melanotan II is a non-selective melanocortin receptor agonist that simultaneously affects pigmentation, sexual function, appetite, and inflammation through MC1R through MC5R activation. • Melanotan II produces UV-independent tanning by directly stimulating melanocytes to produce eumelanin, the protective dark pigment, without requiring sun exposure. • The sexual arousal effects observed with Melanotan II directly led to the development of PT-141, a more targeted derivative that became the first FDA-approved peptide for sexual dysfunction. • Melanotan II has a notably broad side effect profile including nausea and facial flushing precisely because it lacks selectivity and activates all five melanocortin receptor subtypes.

Sexual Function Effects

Extensive research demonstrates Melanotan II's pronounced pro-sexual effects through activation of melanocortin-3 and melanocortin-4 receptors (MC3R/MC4R) in hypothalamic nuclei controlling sexual behavior and arousal. Clinical studies in both men and women have documented increased spontaneous erections, enhanced libido, and improved sexual satisfaction scores following subcutaneous administration of the peptide. The sexual enhancement effects occur through central nervous system mechanisms independent of peripheral vascular changes, involving activation of oxytocinergic pathways and modulation of dopamine signaling in reward-related brain circuits. Research has shown onset of sexual function effects within 1-3 hours of administration, with duration of action extending up to 72 hours in some study subjects, making it distinct from fast-acting vasodilator treatments. These findings have positioned Melanotan II as an important research compound for investigating central regulation of sexual function, libido enhancement mechanisms, and the neurobiological connections between melanocortin signaling and sexual motivation pathways.

Fat Metabolism Effects

Emerging research suggests Melanotan II may influence fat metabolism through melanocortin receptor activation in both central and peripheral tissues, with studies documenting effects on lipolysis and adipocyte function. Animal research has shown MC4R activation increases sympathetic nervous system activity to adipose tissue, promoting fatty acid release and oxidation through enhanced beta-adrenergic signaling pathways. Studies indicate the peptide may preferentially affect visceral fat stores, which have higher melanocortin receptor expression than subcutaneous adipose depots, suggesting potential applications in abdominal fat reduction research. Research has documented increased energy expenditure and thermogenesis in treated animals, contributing to negative energy balance independent of appetite suppression effects. These fat metabolism optimization properties position Melanotan II as a research tool for investigating melanocortin-mediated metabolic regulation, body composition modification mechanisms, and the development of novel approaches to obesity and metabolic syndrome research.

Stacking Melanotan II

Melanotan II is usually run on its own rather than in a large stack — there isn't a well-characterized partner compound for it in the current literature. If you do combine it with something, add one compound at a time and see how you respond before layering anything else on top.

Stacking Principles

As a rule, more compounds is not better. Each addition adds cost, injection burden, and another variable to untangle if something feels off. Ask REGEN AI to sanity-check any stack against your goals and bloodwork before you start.

Half-Life & Dosing Cadence

Melanotan II has a reported elimination half-life of ~33 hours. The half-life is the time it takes for blood levels to fall by half, and it's the single biggest driver of how often you dose. That's why the typical schedule lands around as needed (loading then maintenance) at 250–500 mcg — frequent enough to keep levels in a useful range without stacking up. Shorter half-lives mean more frequent dosing and faster clearance if you stop; longer ones mean steadier levels but a slower washout.

Administration & Absorption

Melanotan II is administered by subcutaneous injection (into the fat layer just under the skin). The primary route is subcutaneous. Subcutaneous delivery is absorbed steadily from the fat depot, giving smoother peaks than intramuscular dosing. Whichever route you use, rotate sites and follow sterile technique.

Reconstitution & Handling

Melanotan II ships as a lyophilized (freeze-dried) powder that you reconstitute before use — a common starting point is a 10 mg vial with 2 mL of bacteriostatic water. Add the water slowly down the vial wall, swirl (don't shake), and let it fully dissolve. Reconstituted peptide is refrigerated and used within its stability window; unmixed powder keeps far longer when stored cold and dark. Always confirm exact dosing math against your own vial and concentration.

Onset & Clearance

Because of its ~33 hours half-life, Melanotan II reaches steady levels after a few consistent doses and clears the system within roughly four to five half-lives once you stop. Track how you respond over a defined block rather than judging any single dose, and give the compound enough consistent days before deciding whether it's working. This is educational information, not medical advice — review your protocol with a clinician.